For instance, tumour cells harbouring activating V561M mutation in the FGFR1 kinase domain showed resistance to both specific inhibitors AZD4547 and infigratinib; and non-specific inhibitors, such as ponatinib, TKI258, and lucitanib (E3810) [136]. This evidence concerns the gene FGFR1 and neoplasm.